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Background: Scores for cardio-embolic and bleeding risk in patients with atrial ﬁbrillation are described in the lit-
erature. However, it is not clear how they co-classify elderly patients withmultimorbidity, nor whether and how
they affect the physician's decision on thromboprophylaxis.
Methods: Four scores for cardio-embolic and bleeding risks were retrospectively calculated for≥65 year old pa-
tientswith atrial ﬁbrillation enrolled in the REPOSI registry. The co-classiﬁcation of patients according to risk cat-
egories based on different score combinationswas described and the relationship between risk categories tested.
The association between the antithrombotic therapy received and the scores was investigated by logistic regres-
sions and CART analyses.
Results: At admission, among 543 patients the median scores (range) were: CHADS2 2 (0–6), CHA2DS2–VASc 4
(1–9), HEMORR2HAGES 3 (0–7), HAS-BLED 2 (1–6).Most of the patientswere at high cardio-embolic/high-inter-
mediate bleeding risk (70.5% combining CHADS2 and HEMORR2HAGES, 98.3% combining CHA2DS2–VASc and
HAS-BLED). 50–60% of patientswere classiﬁed in a cardio-embolic risk category higher than the bleeding risk cat-
egory. In univariate and multivariable analyses, a higher bleeding score was negatively associated with warfarin
prescription, and positively associatedwith aspirin prescription. The cardio-embolic scores were associated with
the therapeutic choice only after adjusting for bleeding score or age.
Conclusion:REPOSI patients represented a population at high cardio-embolic and bleeding risks, butmost of them
were classiﬁed by the scores as having a higher cardio-embolic than bleeding risk. Yet, prescription and type of
antithrombotic therapy appeared to be primarily dictated by the bleeding risk.© 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
The underuse of vitamin K antagonists (VKAs) among elderly
patients with atrial ﬁbrillation (AF) has been conﬁrmed in different
settings [1–6]. Indeed, the CHA2DS2–VASc [6,7], that assigns 2 points
(and not 1 as CHADS2 [8]) to age ≥75 years, and 1 point to age
≥65 years would qualify all patients older than 75 years as candi-
dates for long term anticoagulation, and all patients older thanain StreetWest, Hamilton, ON
905 526 8447.
ucci).
i Medicina Interna.
ion of Internal Medicine. Published b65 years for aspirin treatment, even in the absence of other risk fac-
tors [9–11].
Since the fear of treatment-related bleeding is themost likely reason
for the under-prescription of anticoagulants, tools for the prediction of
the risk of bleeding in patients with AF on VKAs have been proposed
[12–15]. All the available scores for bleeding risk include older age
among risk factors. The different therapeutic guidelines frame their
recommendations on the degree of cardio-embolic risk based upon
CHADS2 or CHA2DS2–VASc, but fail to express uniform agreement on
the use and usefulness of bleeding scores, although suggesting of
considering the patient bleeding risk to decide on the long-term
antithrombotic therapy [9–11]. Moreover, it is still controversial wheth-
er and to which extent the decisions on cardio-embolic prophylaxis in
the most common population of patients with AF (the oldest old withy Elsevier B.V. All rights reserved.
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embolic and bleeding risks.
With this background, we analyze retrospectively patients older
than 65 years with atrial ﬁbrillation or ﬂutter (AFF) enrolled in REPOSI
[16] during the ﬁrst (2008) and the second (2010) collection waves of
this registry, with the aims to describe: i) the stratiﬁcation of patients
according to the different scores for cardio-embolic and bleeding risks;
ii) the within-patient relationship between cardio-embolic and bleed-
ing risks as deﬁned by these scores; iii) whether or not the prescription
of antithrombotic therapy was related to the score-based assessment of
cardio-embolic and bleeding risks.
2. Materials and methods
2.1. Study population
Patients analyzed in this study were recruited in the frame of the
‘REgistro POliterapie SIMI’ (REPOSI) [16]. The REPOSI is a collaborative
and independent Registry organized by the Italian Society of Internal
Medicine (SIMI) and the Mario Negri Institute of Pharmacological
Research in Milan with the purpose to create a network of internal
medicine and geriatric wards in order to evaluate hospitalized patients
older than 65 years affected by multiple diseases and prescribed with
polypharmacy. Patients recruited for REPOSI in 2008 and 2010, and
admitted to the participating Italian wards with a known diagnosis of
AFF (International Classiﬁcation of Diseases — Ninth Revision [ICD-9]
codes 427.31 or 427.32) were analyzed in this study. Patients newly
diagnosed with AFF during the index hospitalization were not included.
2.2. Cardio-embolic and bleeding risk stratiﬁcation
The patient population was retrospectively classiﬁed according to
the cardio-embolic risk as predicted by CHADS2 and CHA2DS2–VASc
scores [6,7], and according to the bleeding risk as predicted by
HEMORR2HAGES and HAS-BLED scores [12,14]. The components of
each score, the annual event rates associated with the risk categories
as reported in the literature, as well as the corresponding absolute risk
reduction or increase with VKAs are summarized in online Appendix
A. The scores were retrospectively calculated for each patient using
the data collected at admission on socio-demographic characteristics,
clinical history and drug use before the hospitalization and the reason
for hospitalization. A modiﬁed HEMORR2HAGES score not including
genetic risk factors, and a modiﬁed HAS-BLED score, not including the
labile INR factor were used, because the corresponding data were not
available in REPOSI; both these modiﬁed versions of the scores have
already been used and validated [12,14,17]. The resulting risks were
reported both as continuous scores and as categories (low, intermedi-
ate, high), using for the latter the originally proposed score-based strat-
iﬁcations [6,12,14,17,18] (online Appendix A). Classiﬁcation of patients'
cardio-embolic risk was compared using both scores, and the classiﬁca-
tion of patients' bleeding risk using both scores. We then described the
co-stratiﬁcation of the study population using both a scheme for the
cardio-embolic risk and one for the bleeding risk, testing different
combinations. Correlation between scores, as a measure for trend, was
tested by the Spearman test. Concordance/discordance between risk
categories was expressed as percentage of patients classiﬁed into the
same/different risk category. Although risk categories are categorical
ordinal variables, linear regression analyses were used to show the
average association between the risk categories as deﬁned using the
different scores. For this purpose the low, intermediate and high risk
categories were coded as 0, 1 and 2, respectively.
2.3. Antithrombotic therapy and risk scores
The study population was characterized according to the anti-
thrombotic therapy recorded at hospital admission, considering aslong-term therapy VKAs and antiplatelet drugs (aspirin, clopidogrel,
ticlopidine and aspirin plus dypyridamole). To evaluate retrospectively
the association between the cardio-embolic/bleeding risk scores and
the prescribed antithrombotic therapy, two sets of analyses were
performed.
a. Risk scores as predictors of VKA prescription. A classic logistic regres-
sion was used to evaluate this relationship, in simple and multivari-
able analyses (including both cardio-embolic and bleeding score as
predictors). CART (Classiﬁcation and Regression Trees analysis)
[19] was also used as a multivariable approach to further explore
how the scores were hierarchically associated with VKA prescrip-
tion. The program automatically selected for each score the best-
splitting value for the therapeutic choice, i.e. that value above or
below which VKAs were more likely to be prescribed or not.
b. Risk scores as predictors of antithrombotic therapy type. With the aim
of taking into account all thepossible antithrombotic options for AFF,
a 4-level nominal variable was also used as dependent variable,
coded as 0 for no therapy, 1 for antiplatelet therapy, 2 for VKAs,
and 3 for VKAs plus antiplatelet agents. The variable levelswere cho-
sen in order to simulate an ordinal variable where each further level
corresponded to an increasing antithrombotic burden. The associa-
tion between this variable and the scores was explored using an or-
dered logistic regression when the proportional odds assumption
was met, i.e. when the effect of the score on each therapeutic step
was constant (the omodel user's command for STATA was used to
verify the assumption). If this assumptionwas notmet, amultinomi-
al logistic regression was used, where the no-therapy choice was
taken as reference and the association of the score with any other
therapeutic choice was compared to the reference.
Then the analyses exploring the association between the risk scores
and antithrombotic therapy were repeated adjusting for patient age, in
order to look at the effect of the scores after holding the patient age con-
stant; this is equivalent to remove the effect of age (a component of the
scores) from the effect of the scores.
In order to take into account the multi-center origin of the REPOSI
data, we adopted robust variance estimates that were obtained in all
regression models by means of the Huber/White/sandwich estimator
which considers observations as independent across groups (the REPOSI
centers in this case).
STATA was used to perform all the analyses (version 12, Statacorp,
College Station, Tx, US).
3. Results
3.1. Study population
The 2008–2010 installments of REPOSI included 2712 patients, 1332
enrolled in 2008 and 1380 in 2010. Five hundred and forty-three
patients (20.0%) were admitted to hospital with a known diagnosis of
AFF, 247 in 2008 (18.5%) and 296 in 2010 (21.4%). Patients with AFF
at admission (Table 1) were signiﬁcantly older than those without
(median age = 81.1, range 65.4–100.6 years, versus median age =
78.6, range 65.0–101.4 years, p b 0.001); approximately 80% of patients
were older than 75 years. Two hundred sixty-ﬁve were males (48.8%),
with no difference in gender composition compared to patients without
AFF. Twenty-eight patients with AFF at admission (5%) died during the
hospitalization. Table 1 shows also the proportion of patients presenting
a stroke or a bleeding event as reason for admission or during the
hospital stay.
3.2. Cardio-embolic and bleeding risk stratiﬁcation
Table 1 reports the mean and median score values at admission.
Table 2 shows how the study population was stratiﬁed into cardio-
embolic and bleeding risk categories based upon the different scores.
Table 1
Demographic and clinical characteristics of the study population.a
Characteristic
Male, n (%) 265 (48.8)
Mean age ± SD (median, range) 81.0 ± 7.3 (81.1, 65.4–100.6)
Median number of drugs per patient (range) 6 (1–15)
Mean CHADS2 ± SD (median, range) 2.2 ± 1.1 (2, 0–6)
Mean CHA2DS2–VASc ± SD (median, range) 3.8 ± 1.2 (4, 1–9)
Mean HEMORR2HAGES ± SD (median, range) 2.6 ± 1.2 (3, 0–7)
Mean HAS-BLED ± SD (median, range) 2.6 ± 1.1 (2, 1–6)
Oral antithrombotic therapy at admission, n (%)b
Vitamin K antagonist 210 (38.7)
Antiplatelet agent 174 (32.0)
VKA + antiplatelet 16 (3.0)
None 143 (26.3)
Stroke as reason for admission, n (%) 22 (4.0)
Stroke as adverse event during the hospital stay, n (%) 2 (0.4)
Bleeding as reason for admission, n (%) 16 (2.9)c
Bleeding as adverse event during the hospital stay, n
(%)
8 (1.5)c
a The risk scores were calculated counting the risk factors at admission.
b 15% of patients not receiving VKAs at admission were on lowmolecular weight hepa-
rin (LMWH) or fondaparinux at therapeutic or prophylactic doses.
c Two patients presented a bleeding event both as reason for admission and during the
hospital stay.
Table 3
Patient distribution according to cardio-embolic and bleeding risk categories: number of
patients (% of the whole population).
HEMORR2HAGES
CHADS2
Low risk
Intermediate 
risk
High risk Total
Low risk 11 (2.0) 5 (0.9) −
Intermediate risk 47 (8.7) 62 (11.4) 9 (1.7)
High risk 26 (4.8) 273 (50.3) 110 (20.2)
543 (100)
HAS-BLED
CHA2DS2–VASc
Low risk
Intermediate 
risk
High risk Total
Low risk − − −
Intermediate risk − 8 (1.5) 1 (0.2)
High risk − 270 (49.7) 264 (48.6)
543 (100)
According to the predicted risk associated with the scores reported in the original papers
(see the online Appendix A for details): White cells: the predicted annualized cardio-
embolic risk tends to be larger than the predicted annualized bleeding risk (and the pre-
dicted absolute risk reduction of cardio-embolic events with warfarin tends to be larger
than the predicted absolute risk increase of bleeding events with warfarin). Dark gray
cells: the predicted annualized bleeding risk tends to be larger than the predicted annual-
ized cardio-embolic risk (and the predicted absolute risk increase of bleeding events with
warfarin tends to be larger than the predicted absolute risk reduction of cardio-embolic
events with warfarin). Light gray cells: the predicted annualized bleeding risk tends to
be equal or larger than thepredicted annualized cardio-embolic risk (and the predicted ab-
solute risk increase of bleeding events with warfarin tends to be equal or larger than the
predicted absolute risk reduction of cardio-embolic events with warfarin). Predicted de-
notes as reported in score validation studies.
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scores (Spearman correlation coefﬁcient 0.86, p value b 0.001), but
with a discordance of 25% between the two risk classiﬁcations. In detail,
all patients classiﬁed at intermediate or high risk using CHADS2 were
classiﬁed at high risk according to CHA2DS2–VASc; patients with a low
cardio-embolic risk according to CHADS2 were reclassiﬁed by
CHA2DS2–VASc as having an intermediate (9 of 16, 56%) or a high (7
of 16, 43%) risk. There was a high correlation between the two bleeding
risk scores (Spearman correlation coefﬁcient 0.82, p value b 0.001), but
with a discordance of 43% between the two risk classiﬁcations. In detail,
nearly all (117 of 119, 98%) patients classiﬁed at high risk according
to HEMORR2HAGES were classiﬁed at high risk also according to HAS-
BLED; 57% (193/340) of patients classiﬁed at intermediate risk ac-
cording to HEMORR2HAGES were also classiﬁed at intermediate risk
according to HAS-BLED, whereas the remaining 43% patients (147/340)
were classiﬁed at high HAS-BLED risk. Patients with a low bleeding
risk according to HEMORR2HAGES were classiﬁed at intermediate
(83 among 84, 99%) or, in one case only, at high HAS-BLED risk. Fig. 1
(plots a and b) in the online Appendix B exempliﬁes the average rela-
tionship between risk categories deﬁned by each couple of scores.Table 2
Risk stratiﬁcation according to cardio-embolic and bleeding scores.
a. Cardio-embolic risk scores
Cardio-embolic risk
category
CHADS2 CHA2DS2–VASc
Score Number of
patients
% Score Number of
patients
%
Low 0 16 3.0 0 0 0
Intermediate 1 118 21.7 1 9 1.7
High ≥2 409 75.3 ≥2 534 98.3
b. Bleeding risk scores
Bleeding risk category HEMORR2HAGES HAS-BLED
Score Number of
patients
% Score Number of
patients
%
Low 0–1 84 15.5 0 0 0
Intermediate 2–3 340 62.6 1–2a 278 51.2
High ≥4 119 21.9 ≥3 265 48.8
a 60 patients (11.0%) had a HAS-BLED score 1.Table 3 shows how the study populationwas co-classiﬁed according
to both the cardio-embolic and bleeding risks using two different
score combinations. The Spearman correlation between CHADS2 and
HEMORR2HAGES scores and between CHA2DS2–VASc and HAS-BLED
scores was, respectively, 0.424 and 0.316. Most of the patients were at
high cardio-embolic/high-intermediate bleeding risk (70.5% when
CHADS2 plus HEMORR2HAGES were used, 98.3% when CHA2DS2–VASc
plus HAS-BLED were used). Plots c, d, e and f in Fig. 1 (online
Appendix A) show the average relationship between cardio-embolic
and bleeding risk categories using the 4 possible score combinations.
3.3. Antithrombotic therapy and risk scores
The antithrombotic therapy that REPOSI patients were receiving
at admission is shown in Table 1.
3.3.1. Risk scores as predictors of VKA prescription
Table 4 reports the number and percentage of patients on VKAs in
each cell co-deﬁned by the cardio-embolic and bleeding risk. The
highest rate of VKA prescription was found among patients at inter-
mediate cardio-embolic and low bleeding risk when the CHADS2/
HEMORR2HAGES co-classiﬁcation was used, and among patients at
high cardio-embolic and intermediate bleeding risk when the
CHA2DS2–VASc/HAS-BLED combination was used (ignoring the 100%
cell including only 1 patient). In simple logistic regressions, a higher
bleeding score, using either HEMORR2HAGES or HAS-BLED, was associ-
ated with a lower probability to receive VKA (p b 0.001). Neither
cardio-embolic risk score was signiﬁcantly associated with VKAs
prescription in unadjusted analysis. Only after adjusting for the bleeding
risk score (either HEMORR2HAGES or HAS-BLED) was a higher cardio-
embolic risk score (either CHADS2 or CHA2DS2–VASc) associated with
a higher probability to receive VKAs (p b 0.001 for any combination).
When all the 4 scoreswere included as covariates, the HEMORR2HAGES
Table 4
Frequency of VKA prescription according to cardio-embolic and bleeding risk categories:
number of patients (% of the total number of patients in each cell).
HEMORR2HAGES
CHADS2
Low risk
Intermediate 
risk
High risk
Low risk 4 (36.4) 1 (20.0) − 5 (31.2)
Intermediate risk 31 (66.0) 19 (30.6) 0 (0.0) 40 (33.9)
High risk 16 (61.5) 130 (47.6) 25 (22.7) 171 (41.8)
HAS-BLED
CHA2DS2–VASc
Low risk
Intermediate 
risk
High risk
Low risk − − − −
Intermediate risk − 2 (25.0) 1 (100.0) 3 (33.3)
High risk − 150 (55.6) 73 (27.6) 223 (41.8)
According to the predicted risk associated with the scores reported in the original papers
(see the online Appendix A for details): White cells: the predicted annualized cardio-
embolic risk tends to be larger than the predicted annualized bleeding risk (and the pre-
dicted absolute risk reduction of cardio-embolic events with warfarin tends to be larger
than the predicted absolute risk increase of bleeding events with warfarin). Dark gray
cells: the predicted annualized bleeding risk tends to be larger than the predicted annual-
ized cardio-embolic risk (and the predicted absolute risk increase of bleeding events with
warfarin tends to be larger than the predicted absolute risk reduction of cardio-embolic
events with warfarin). Light gray cells: the predicted annualized bleeding risk tends to
be equal or larger than thepredicted annualized cardio-embolic risk (and thepredicted ab-
solute risk increase of bleeding events with warfarin tends to be equal or larger than the
predicted absolute risk reduction of cardio-embolic events with warfarin). Predicted de-
notes as reported in score validation studies.
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conﬁrmed these results, and pointed out that a low bleeding risk score
seemed to affect positively the probability of VKA prescription, whereas
cardio-embolic risk scores were associated with the probability of VKA
prescription only among higher bleeding risk scores (Fig. 2 in the online
Appendix A).
3.3.2. Risk scores as predictors of the type of antithrombotic therapy
When an ordered 4-level variable was used for antithrombotic ther-
apy, the proportional odds assumptionwasmet for both cardio-embolic
risk scores, i.e. higher scoreswere associated to therapeutic choiceswith
a higher antithrombotic potency, but in a quasi statistically signiﬁcant
way only for CHADS2 (p = 0.054). The proportional odds assumption
was notmet for the bleeding risk scores. In simplemultinomial analysis,
and also after adjusting for any cardio-embolic risk score, theHEMORR2-
HAGES scorewas associatedwith the therapeutic choice, but in different
ways: a higher HEMORR2HAGES score was negatively associated with
the prescription of VKA compared to no therapy, but it was positively
associated with the prescription of antiplatelet agents compared to no
therapy. A direct association between a higher score and antiplatelet
prescription was also found for the HAS-BLED score in simple multino-
mial logistic regression, and after adjusting for any cardio-embolic risk
score. Conversely HAS-BLED was not associated with the prescription
of VKA. None of the reported ﬁndings changed when patients on
LMWH or fondaparinux were excluded from the analyses. After
adjusting for patient age, both the cardio-embolic risk scores became
signiﬁcantly associated with the antithrombotic therapy in all types of
analysis even without adjusting for the bleeding risk scores. All the
remaining results did not change.
4. Discussion
The REPOSI registry was designed in order to collect data on a repre-
sentative sample of patients admitted to internal medicine wards, in-
creasingly characterized in Italy and elsewhere in Europe by advancedage and multimorbidity. The ﬁrst aim of these post-hoc analyses was
to describe how the available scores for cardio-embolic and bleeding
risks would classify patients with AFF in this complex population. We
then evaluated whether or not risk assessment according to the scores
was related the choice of antithrombotic therapy.
The main novelty of this study was to look, albeit retrospectively, at
the co-classiﬁcation of this elderly population using a combination
of scores for both cardio-embolic and bleeding risk, that might theoret-
ically provide the physician with a higher potential for tailoring each
individual treatment than using a strategy based only on the cardio-
embolic. As expected, the REPOSI population was on average both at
high cardio-embolic and bleeding risk (see Table 2a), even though the
patients' cardio-embolic risk category tended to be higher than the
bleeding risk category. In particular, the percentage of patients belong-
ing to a cardio-embolic risk category higher than the bleeding risk cate-
gory was more than 60% when CHADS2 plus HEMORR2HAGES were
jointly used, and approximately 50% when CHA2DS2–VASc plus HAS-
BLED were used. This co-classiﬁcation would apparently lead to re-
commend anticoagulation for approximately 50% of REPOSI patients.
However, the same deﬁnitions for risk category (i.e. low, intermediate
or high) for different scores do not correspond to the same annual risk
of stroke or bleeding (and so to the same absolute effect of the treat-
ment), as reported in the online Appendix A. In addition, a more appro-
priate way of using the score-based predictions of risk to individualize
treatment recommendations should take into account also the different
weight that a patient might assign to such clinical events, as stroke and
bleeding [20–22].
Our data conﬁrm thewell-known reclassiﬁcation effect of CHA2DS2–
VASc [6,7,19], whichmoved almost all patients at low and intermediate
CHADS2 score to the high risk category. As expected by deﬁnition for a
≥65 year population, none of the REPOSI patients was classiﬁed as hav-
ing a low CHA2DS2–VASc risk [7,19], with the implication that according
to this score all REPOSI patients with AFF would be treated with
anticoagulants.
The cardio-embolic risk stratiﬁcation of REPOSI patients resembled
that recently described in an elderly cohort from the UK General Prac-
tice Research Database (GPRD) [5]. However, the REPOSI population
had a higher representation of patients at intermediate-high CHADS2
score, presumably because of a higher mean age and different selection
criteria (patients at the time of hospital admission, with a likely higher
rate of morbidity than those referred to general practitioners).
There was also a high representation of the high risk category for
bleeding among REPOSI patients, higher than in the UK cohort [5]. As
for the cardio-embolic scores, a reclassiﬁcation effect with HAS-BLED
was observed compared to HEMORR2HAGES. Indeed, none of the
REPOSI patients was at low HAS-BLED risk (because of age, none had a
0 score), and in 40% of them HAS-BLED classiﬁed patients into a higher
risk category than HEMORR2HAGES. This effect was attenuated provid-
ed that a HAS-BLED score of 1 was included in the low risk category
together with score 0 (as done in other studies [5,18]), yet only 11% of
patients had a HAS-BLED score of 1. In fact, HAS-BLED was developed
in order to provide a therapeutic guideline easier to memorize and
includes more practicable risk factors than HEMORR2HAGES [14].
We observed a low overall rate of prescription of VKAs, conﬁrming a
previous analysis based on REPOSI [16]. More interesting, the distribu-
tion of the percentages of patients treated with VKAs across the cells
deﬁned by the scores (Table 3) and the results of the logistic analyses
showed that the patient's bleeding risk, but not the cardio-embolic
risk alone, predicted the therapeutic choice. These ﬁndings on the rela-
tionship between the bleeding score and VKA prescription are consis-
tent with those of the UK cohort [5]. In the literature, evidence on the
relationship between cardio-embolic scores and VKA prescription in
real settings is not uniform [5,23,24]. In the present study, the cardio-
embolic risk was a predictor of VKA prescription, only after adjusting
for the bleeding score or patient age. In addition, the association found
between a higher bleeding score and antiplatelet therapy clearly
804 M. Marcucci et al. / European Journal of Internal Medicine 24 (2013) 800–806conﬁrms the tendency to prescribe aspirin in clinical practice when
evidence or perception of a higher risk of bleeding prevents VKA
prescription. Irrespective of the cardio-embolic risk, this situation
materializes especially in the elderly, even though this behavior is not
justiﬁed by a safer proﬁle of aspirin compared to VKAs [25,26], and
either by a clear efﬁcacy of aspirin [27].
This study has several limitations. First, a certain degree of
underreporting is expected because of the post-hoc nature of our
research question. Thus, it is possible that the actual risk scores were
underestimated. Second, thiswas only an indirect and theoretical inves-
tigation of the association between patients' risks and physician's deci-
sions, because it is not knownwhether or not REPOSI physicians applied
these scores to take decisions. Another limitation is the assumption that
the risk scores proposed in the literature for patients with AFF have a
good predictive ability in a REPOSI-like elderly population. A further
fundamental step should be the evaluation of the impact on patient
outcomes of a decision strategy based on combined cardio-embolic
and bleeding risk assessment compared to a strategy of cardio-
embolic risk assessment alone.
Learning points
• Scores for cardio-embolic and bleeding risk in patients with atrial
ﬁbrillation are described in the literature to aid at tailoring the long
term antithrombotic therapy; all of them include age as risk factor.
• We observed how the available scores (CHADS2 and CHA2DS2–VASc,
for cardio-embolic risk, and HEMORR2HAGES and HAS-BLED, for
bleeding risk) co-classiﬁed complex elderly patients with multi-
morbidity admitted to Italian internal medicine and geriatric wards,
and we conﬁrmed that they conﬁgured a population both at high
cardio-embolic and at high bleeding risk.
• 50–60% of patients (depending on the score couples used) were
classiﬁed in a cardio-embolic risk category higher than the bleeding
risk category.
• In those patients, the prescription and the type of antithrombotic
therapy appeared to be primarily inﬂuenced by the bleeding risk;
both the cardio-embolic scores were associated with the therapeutic
choice only after adjusting for the patient bleeding score or age.Conﬂict of interest
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